InflaRx IFRX
NASDAQ IFRX
$2.05 -0.04 (-1.91%)
As of: Sep 10, 2026 · 3:59 PM EDT

InflaRx (IFRX) Debt Ratio (2020 - 2025)

InflaRx's (IFRX) quarterly Debt Ratio came in at 0.06 in Q2 2025, up 4705.05% quarter-over-quarter from 0.0 in Q3 2022.

Analysis

InflaRx (IFRX) Debt Ratio (2020 - 2025) Analysis & Trends

InflaRx has disclosed Debt Ratio across 4 years of filings, most recently posting 0.06 for Q2 2025.

  • In Q2 2025, Debt Ratio changed N/A year-over-year to 0.06; the TTM figure through Jun 2025 stood at 0.06 (changed N/A YoY), while the FY2021 annual figure was 0.0, down 17.24% from the prior year.
  • Debt Ratio came in at 0.06 for Q2 2025 at InflaRx, up from 0.0 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.06 in Q2 2025 to a low of 0.0 in Q2 2021.
  • Average Debt Ratio over 3 years is 0.01, with a median of 0.0 recorded in 2022.
  • The largest YoY upside for Debt Ratio was 22.84% in 2022 against a maximum downside of 53.08% in 2022.
  • Over 3 years, Debt Ratio stood at 0.0 in 2021, then increased by 16.74% to 0.0 in 2022, then soared by 4705.05% to 0.06 in 2025.
  • Per Business Quant data, the three most recent Debt Ratio figures were 0.06 in Q2 2025, 0.0 in Q3 2022, and 0.0 in Q2 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 0.66
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 0.58
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 0.05
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 0.05
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 0.25
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 InflaRx 139.29 Mn -44.96 Mn 2.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 0.06
Sep 30, 2022 0.00
Jun 30, 2022 0.00
Mar 31, 2022 0.00
Dec 31, 2021 0.00
Jun 30, 2021 0.00
Mar 31, 2021 0.00
Dec 31, 2020 0.00